Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can frequent CRP checks prevent relapses in giant cell arteritis?

NCT ID NCT07720804

Knowledge-focused Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This pilot study is investigating how quickly C-reactive protein (CRP), a key marker of inflammation, drops after starting steroid treatment in people newly diagnosed with giant cell arteritis. By measuring CRP levels daily, then weekly and monthly for up to a year, researchers hope to understand how CRP changes relate to symptoms and whether early normalization could guide treatment adjustments to avoid complications or relapses. The study involves 40 adults hospitalized with a new diagnosis of giant cell arteritis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood tests to measure C-reactive protein (CRP) levels
What this could lead to
If successful, this could help doctors personalize steroid dosing for giant cell arteritis, potentially reducing complications and relapses.
What could go wrong
This is a small pilot study with only 40 participants, so findings may not apply to all patients. It is observational and does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged 18 or older hospitalized in the internal medicine department with a new diagnosis of ACG * Personne affiliée ou bénéficiaire d'un régime de sécurité sociale * Free and informed consent signed by the participant and the investigator Exclusion Criteria: * Patients scheduled to be placed on a sparing regimen during hospitalization * Patients with renal insufficiency (eGFR ≤ 60 mL/min/1.73 m²) * Patients with a history of corticosteroid-treated pseudopolyarthritis * Patients with ACG and visual impairment (severity criterion) * Patients on immunosuppressants or biologic therapy * HIV infection or progressive malignancy * Known poor treatment adherence * Dementia * Pregnant or breastfeeding women * Patients under legal guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Giant cell arteritis (GCA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Giant Cell Arteritis temporal arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Giant cell arteritis (GCA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.